Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
27
CLDX Quote, Financials, Valuation and Earnings
Last price:
$23.50
Seasonality move
:
-2.68%
Day range:
$22.63 - $23.60
52-week range:
$14.40 - $30.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
601.06x
P/B ratio:
2.61x
Volume:
582.3K
Avg. volume:
652.6K
1-year change:
2.13%
Market cap:
$1.6B
Revenue:
$7M
EPS (TTM):
-$3.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CLDX
Celldex Therapeutics, Inc.
|
$1.5M | -$1.00 | -9.83% | -30.49% | $53.36 |
|
ABEO
Abeona Therapeutics, Inc.
|
$5.6M | -$0.34 | -97.62% | -57.23% | $20.64 |
|
ATOS
Atossa Therapeutics, Inc.
|
-- | -$1.14 | -- | -1919.23% | $80.00 |
|
CLCS
Cell Source, Inc.
|
-- | -- | -- | -- | -- |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
$1.5M | -$0.70 | 3650% | -11.09% | $11.00 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CLDX
Celldex Therapeutics, Inc.
|
$23.54 | $53.36 | $1.6B | -- | $0.00 | 0% | 601.06x |
|
ABEO
Abeona Therapeutics, Inc.
|
$5.29 | $20.64 | $286.7M | 4.54x | $0.00 | 0% | 715.16x |
|
ATOS
Atossa Therapeutics, Inc.
|
$4.42 | $80.00 | $38.1M | -- | $0.00 | 0% | -- |
|
CLCS
Cell Source, Inc.
|
$0.8500 | -- | $38.3M | -- | $0.00 | 0% | -- |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
$2.06 | $11.00 | $7.6M | -- | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.29 | $5.50 | $40.2M | -- | $0.00 | 0% | 4.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CLDX
Celldex Therapeutics, Inc.
|
0.44% | 1.179 | 0.15% | 12.42x |
|
ABEO
Abeona Therapeutics, Inc.
|
12.34% | -1.035 | 8.71% | 9.35x |
|
ATOS
Atossa Therapeutics, Inc.
|
-- | 0.662 | -- | 6.32x |
|
CLCS
Cell Source, Inc.
|
-- | -0.372 | -- | -- |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
1.77% | 0.329 | 4.23% | 7.51x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.387 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CLDX
Celldex Therapeutics, Inc.
|
-$824K | -$73.6M | -32.02% | -32.17% | -8747.53% | -$49.1M |
|
ABEO
Abeona Therapeutics, Inc.
|
-$1.4M | -$24M | 70.47% | 88.36% | -5698% | -$23.7M |
|
ATOS
Atossa Therapeutics, Inc.
|
-$4K | -$9.3M | -47.46% | -47.46% | -- | -$6M |
|
CLCS
Cell Source, Inc.
|
-- | -$831.6K | -- | -- | -- | -$639K |
|
KPRX
Kiora Pharmaceuticals, Inc.
|
-$38.2K | -$2.5M | -34.13% | -34.44% | 82.56% | -$1.3M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Celldex Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CLDX or ABEO?
Abeona Therapeutics, Inc. has a net margin of -7753.43% compared to Celldex Therapeutics, Inc.'s net margin of --. Celldex Therapeutics, Inc.'s return on equity of -32.17% beat Abeona Therapeutics, Inc.'s return on equity of 88.36%.
Company Gross Margin Earnings Per Share Invested Capital CLDXCelldex Therapeutics, Inc.-19.59% -$1.01 $601M ABEOAbeona Therapeutics, Inc.-117% -$0.10 $195.3M -
What do Analysts Say About CLDX or ABEO?
Celldex Therapeutics, Inc. has a consensus price target of $53.36, signalling upside risk potential of 126.67%. On the other hand Abeona Therapeutics, Inc. has an analysts' consensus of $20.64 which suggests that it could grow by 290.22%. Given that Abeona Therapeutics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Abeona Therapeutics, Inc. is more attractive than Celldex Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLDXCelldex Therapeutics, Inc.12 2 0 ABEOAbeona Therapeutics, Inc.6 0 0 -
Is CLDX or ABEO More Risky?
Celldex Therapeutics, Inc. has a beta of 1.242, which suggesting that the stock is 24.184% more volatile than S&P 500. In comparison Abeona Therapeutics, Inc. has a beta of 1.175, suggesting its more volatile than the S&P 500 by 17.515%.
-
Which is a Better Dividend Stock CLDX or ABEO?
Celldex Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abeona Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celldex Therapeutics, Inc. pays -- of its earnings as a dividend. Abeona Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLDX or ABEO?
Celldex Therapeutics, Inc. quarterly revenues are --, which are smaller than Abeona Therapeutics, Inc. quarterly revenues of --. Celldex Therapeutics, Inc.'s net income of -$67M is lower than Abeona Therapeutics, Inc.'s net income of -$5.2M. Notably, Celldex Therapeutics, Inc.'s price-to-earnings ratio is -- while Abeona Therapeutics, Inc.'s PE ratio is 4.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celldex Therapeutics, Inc. is 601.06x versus 715.16x for Abeona Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLDXCelldex Therapeutics, Inc.601.06x -- -- -$67M ABEOAbeona Therapeutics, Inc.715.16x 4.54x -- -$5.2M
-
Which has Higher Returns CLDX or ATOS?
Atossa Therapeutics, Inc. has a net margin of -7753.43% compared to Celldex Therapeutics, Inc.'s net margin of --. Celldex Therapeutics, Inc.'s return on equity of -32.17% beat Atossa Therapeutics, Inc.'s return on equity of -47.46%.
Company Gross Margin Earnings Per Share Invested Capital CLDXCelldex Therapeutics, Inc.-19.59% -$1.01 $601M ATOSAtossa Therapeutics, Inc.-- -$0.07 $49.8M -
What do Analysts Say About CLDX or ATOS?
Celldex Therapeutics, Inc. has a consensus price target of $53.36, signalling upside risk potential of 126.67%. On the other hand Atossa Therapeutics, Inc. has an analysts' consensus of $80.00 which suggests that it could grow by 1455.43%. Given that Atossa Therapeutics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Celldex Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLDXCelldex Therapeutics, Inc.12 2 0 ATOSAtossa Therapeutics, Inc.3 0 0 -
Is CLDX or ATOS More Risky?
Celldex Therapeutics, Inc. has a beta of 1.242, which suggesting that the stock is 24.184% more volatile than S&P 500. In comparison Atossa Therapeutics, Inc. has a beta of 1.364, suggesting its more volatile than the S&P 500 by 36.379%.
-
Which is a Better Dividend Stock CLDX or ATOS?
Celldex Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atossa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celldex Therapeutics, Inc. pays -- of its earnings as a dividend. Atossa Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLDX or ATOS?
Celldex Therapeutics, Inc. quarterly revenues are --, which are smaller than Atossa Therapeutics, Inc. quarterly revenues of --. Celldex Therapeutics, Inc.'s net income of -$67M is lower than Atossa Therapeutics, Inc.'s net income of -$8.7M. Notably, Celldex Therapeutics, Inc.'s price-to-earnings ratio is -- while Atossa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celldex Therapeutics, Inc. is 601.06x versus -- for Atossa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLDXCelldex Therapeutics, Inc.601.06x -- -- -$67M ATOSAtossa Therapeutics, Inc.-- -- -- -$8.7M
-
Which has Higher Returns CLDX or CLCS?
Cell Source, Inc. has a net margin of -7753.43% compared to Celldex Therapeutics, Inc.'s net margin of --. Celldex Therapeutics, Inc.'s return on equity of -32.17% beat Cell Source, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CLDXCelldex Therapeutics, Inc.-19.59% -$1.01 $601M CLCSCell Source, Inc.-- -$0.04 -- -
What do Analysts Say About CLDX or CLCS?
Celldex Therapeutics, Inc. has a consensus price target of $53.36, signalling upside risk potential of 126.67%. On the other hand Cell Source, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Celldex Therapeutics, Inc. has higher upside potential than Cell Source, Inc., analysts believe Celldex Therapeutics, Inc. is more attractive than Cell Source, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLDXCelldex Therapeutics, Inc.12 2 0 CLCSCell Source, Inc.0 0 0 -
Is CLDX or CLCS More Risky?
Celldex Therapeutics, Inc. has a beta of 1.242, which suggesting that the stock is 24.184% more volatile than S&P 500. In comparison Cell Source, Inc. has a beta of -225.097, suggesting its less volatile than the S&P 500 by 22609.671%.
-
Which is a Better Dividend Stock CLDX or CLCS?
Celldex Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cell Source, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celldex Therapeutics, Inc. pays -- of its earnings as a dividend. Cell Source, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLDX or CLCS?
Celldex Therapeutics, Inc. quarterly revenues are --, which are larger than Cell Source, Inc. quarterly revenues of --. Celldex Therapeutics, Inc.'s net income of -$67M is lower than Cell Source, Inc.'s net income of -$1.4M. Notably, Celldex Therapeutics, Inc.'s price-to-earnings ratio is -- while Cell Source, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celldex Therapeutics, Inc. is 601.06x versus -- for Cell Source, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLDXCelldex Therapeutics, Inc.601.06x -- -- -$67M CLCSCell Source, Inc.-- -- -- -$1.4M
-
Which has Higher Returns CLDX or KPRX?
Kiora Pharmaceuticals, Inc. has a net margin of -7753.43% compared to Celldex Therapeutics, Inc.'s net margin of 84.08%. Celldex Therapeutics, Inc.'s return on equity of -32.17% beat Kiora Pharmaceuticals, Inc.'s return on equity of -34.44%.
Company Gross Margin Earnings Per Share Invested Capital CLDXCelldex Therapeutics, Inc.-19.59% -$1.01 $601M KPRXKiora Pharmaceuticals, Inc.-- $0.01 $22.8M -
What do Analysts Say About CLDX or KPRX?
Celldex Therapeutics, Inc. has a consensus price target of $53.36, signalling upside risk potential of 126.67%. On the other hand Kiora Pharmaceuticals, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 433.98%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Celldex Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLDXCelldex Therapeutics, Inc.12 2 0 KPRXKiora Pharmaceuticals, Inc.0 0 0 -
Is CLDX or KPRX More Risky?
Celldex Therapeutics, Inc. has a beta of 1.242, which suggesting that the stock is 24.184% more volatile than S&P 500. In comparison Kiora Pharmaceuticals, Inc. has a beta of -0.819, suggesting its less volatile than the S&P 500 by 181.948%.
-
Which is a Better Dividend Stock CLDX or KPRX?
Celldex Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiora Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celldex Therapeutics, Inc. pays -- of its earnings as a dividend. Kiora Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLDX or KPRX?
Celldex Therapeutics, Inc. quarterly revenues are --, which are smaller than Kiora Pharmaceuticals, Inc. quarterly revenues of --. Celldex Therapeutics, Inc.'s net income of -$67M is lower than Kiora Pharmaceuticals, Inc.'s net income of $26.8K. Notably, Celldex Therapeutics, Inc.'s price-to-earnings ratio is -- while Kiora Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celldex Therapeutics, Inc. is 601.06x versus -- for Kiora Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLDXCelldex Therapeutics, Inc.601.06x -- -- -$67M KPRXKiora Pharmaceuticals, Inc.-- -- -- $26.8K
-
Which has Higher Returns CLDX or PSTV?
Plus Therapeutics, Inc. has a net margin of -7753.43% compared to Celldex Therapeutics, Inc.'s net margin of -316.61%. Celldex Therapeutics, Inc.'s return on equity of -32.17% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CLDXCelldex Therapeutics, Inc.-19.59% -$1.01 $601M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About CLDX or PSTV?
Celldex Therapeutics, Inc. has a consensus price target of $53.36, signalling upside risk potential of 126.67%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1778.42%. Given that Plus Therapeutics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Celldex Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLDXCelldex Therapeutics, Inc.12 2 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is CLDX or PSTV More Risky?
Celldex Therapeutics, Inc. has a beta of 1.242, which suggesting that the stock is 24.184% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.
-
Which is a Better Dividend Stock CLDX or PSTV?
Celldex Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celldex Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLDX or PSTV?
Celldex Therapeutics, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Celldex Therapeutics, Inc.'s net income of -$67M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Celldex Therapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celldex Therapeutics, Inc. is 601.06x versus 4.69x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLDXCelldex Therapeutics, Inc.601.06x -- -- -$67M PSTVPlus Therapeutics, Inc.4.69x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 2.28% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is up 7% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is up 3.28% over the past day.
